243 results
Page 4 of 13
PRE 14A
tyqbjj6ufukulib7ng7
10 Aug 20
Preliminary proxy
12:00am
8-K
EX-99.1
aww8o82dq 7zjflwqb
31 Jul 20
Regulation FD Disclosure
4:05pm
10-K
EX-10.2
3083rpfkjs2s 414div6
29 Jun 20
Annual report
4:02pm
10-K
noyhzr108z5v
29 Jun 20
Annual report
4:02pm
8-K
EX-99.1
qbvpd oaiwm8215y6
29 Jun 20
Acasti Pharma Provides Fiscal 2020 Year-End Business Update
12:50pm
S-3
EX-1.2
w15f18a
29 Jun 20
Shelf registration
12:00am
8-K
EX-99.1
s1ot16w wmuxe
19 Jun 20
Acasti Pharma Receives FDA Response to TRILOGY 1 Briefing Package
9:09am
8-K
EX-99.1
mmoi1ljekl9gd6wi
30 Apr 20
Acasti Pharma Announces Submission of TRILOGY 1 Briefing Package to FDA
4:22pm
8-K
EX-99.1
wqfm2dk
20 Apr 20
Acasti Pharma Awarded Notice of Allowance for Second Composition of Matter Patent in Canada
4:05pm
8-K
EX-99.1
0dhlo434
1 Apr 20
Acasti Pharma Submits FDA Meeting Request on Schedule, and FDA Meeting Expected in the Second Half of June
5:12pm
6-K
EX-99.1
n6gp1jp
11 Mar 20
Acasti Pharma Awarded Notice of Allowance for Additional Composition of Matter and Method of Use Patents in the United States and Mexico
8:00am
6-K
EX-99.1
o62e wafn5zvi61y
28 Feb 20
Acasti Receives NASDAQ Notification Regarding Minimum Bid Requirements
5:00pm
6-K
EX-99.1
pqvb29
14 Feb 20
Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2020
8:00am
6-K
EX-99.3
plh92ke2ncnxtci3svv
14 Feb 20
Current report (foreign)
8:00am
6-K
EX-99.4
bc21u58k9 4pcaf
14 Feb 20
Current report (foreign)
8:00am
6-K
EX-99.1
1syc 6ga545net
13 Feb 20
Acasti Pharma Schedules Third Quarter Fiscal 2020 and Business Update Conference Call
9:00am
6-K
EX-99.1
srzm 0smn8i883d92p
10 Feb 20
Acasti Pharma Provides Update on TRILOGY 1 and TRILOGY 2 Phase 3 Trials of CaPre
7:00am
6-K
EX-99.1
hmch5tez8fng 3v
13 Jan 20
Acasti Pharma Reports Topline Results for TRILOGY 1 Phase 3 Trial of CaPre
6:21am
6-K
EX-99.1
6l2xc8azgn e6i8
23 Dec 19
Acasti Pharma Provides Update on Timing of Topline Results for TRILOGY 1 Phase 3 Trial of CaPre
8:43pm
6-K
EX-99.1
3hf1tqf
26 Nov 19
Acasti Pharma Reports Last Patient Visit in TRILOGY 1 Phase 3 Trial of CaPre for the Treatment of Severe Hypertriglyceridemia
7:58am